[go: up one dir, main page]

CR20250275A - NOVEL LINKING DEVICES FOR THE SUSTAINED DELIVERY OF THERAPEUTICS - Google Patents

NOVEL LINKING DEVICES FOR THE SUSTAINED DELIVERY OF THERAPEUTICS

Info

Publication number
CR20250275A
CR20250275A CR20250275A CR20250275A CR20250275A CR 20250275 A CR20250275 A CR 20250275A CR 20250275 A CR20250275 A CR 20250275A CR 20250275 A CR20250275 A CR 20250275A CR 20250275 A CR20250275 A CR 20250275A
Authority
CR
Costa Rica
Prior art keywords
therapeutics
antibody
sustained delivery
linking devices
novel linking
Prior art date
Application number
CR20250275A
Other languages
Spanish (es)
Inventor
Christopher Lopes Daniel
Muppidi Avinash
Wang Yan
Cortez Guillermo
John Stokell David
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20250275A publication Critical patent/CR20250275A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Enlazadores para la conexión de un terapéutico a otro medio, tal como una región Fc de un anticuerpo. Enlazadores con dos o más grupos funcionales maleimida que pueden sufrir reacciones de adiciones conjugadas nucleofílicas. Métodos para aumentar la duración de acción de un terapéutico al unirse a un enlazador novedoso y una región Fc de un anticuerpo. Conjugados anticuerpo-fármaco, que tienen mayor duración de acción sobre el fármaco solo.Linkers for connecting a therapeutic to another medium, such as an Fc region of an antibody. Linkers with two or more maleimide functional groups that can undergo nucleophilic conjugate addition reactions. Methods for increasing the duration of action of a therapeutic by binding to a novel linker and an Fc region of an antibody. Antibody-drug conjugates, which have a longer duration of action than the drug alone.

CR20250275A 2023-01-17 2024-01-16 NOVEL LINKING DEVICES FOR THE SUSTAINED DELIVERY OF THERAPEUTICS CR20250275A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363480113P 2023-01-17 2023-01-17
PCT/US2024/011615 WO2024155591A1 (en) 2023-01-17 2024-01-16 Novel linkers for sustained delivery of therapeutics

Publications (1)

Publication Number Publication Date
CR20250275A true CR20250275A (en) 2025-08-18

Family

ID=89983916

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250275A CR20250275A (en) 2023-01-17 2024-01-16 NOVEL LINKING DEVICES FOR THE SUSTAINED DELIVERY OF THERAPEUTICS

Country Status (13)

Country Link
EP (1) EP4651905A1 (en)
JP (1) JP2026501849A (en)
KR (1) KR20250134235A (en)
CN (1) CN120569221A (en)
AU (1) AU2024210783A1 (en)
CL (1) CL2025002065A1 (en)
CO (1) CO2025009246A2 (en)
CR (1) CR20250275A (en)
DO (1) DOP2025000169A (en)
IL (1) IL321858A (en)
MX (1) MX2025008260A (en)
PE (1) PE20252273A1 (en)
WO (1) WO2024155591A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2710356T3 (en) * 2011-06-17 2019-04-24 Hanmi Science Co Ltd A conjugate comprising oxintomodulin and an immunoglobulin fragment, and use thereof
CN103933575B (en) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 A kind of three flute profile connexons and its application
CN111116745B (en) * 2018-11-01 2022-10-14 上海新理念生物医药科技有限公司 anti-CD79b antibody, drug conjugate thereof and application thereof

Also Published As

Publication number Publication date
CN120569221A (en) 2025-08-29
CL2025002065A1 (en) 2025-09-26
PE20252273A1 (en) 2025-09-15
DOP2025000169A (en) 2025-08-31
JP2026501849A (en) 2026-01-16
AU2024210783A1 (en) 2025-07-31
EP4651905A1 (en) 2025-11-26
CO2025009246A2 (en) 2025-07-28
IL321858A (en) 2025-08-01
MX2025008260A (en) 2025-08-01
WO2024155591A1 (en) 2024-07-25
KR20250134235A (en) 2025-09-10

Similar Documents

Publication Publication Date Title
MX2024008036A (en) Antibody drug conjugates.
CL2021000901A1 (en) Conjugation linkers containing the 2,3-diaminosuccinyl group
CL2019002858A1 (en) Conjugation of a bis-linked cytotoxic drug.
EA202290091A1 (en) CONJUGATE OF A CYTOTOXIC AGENT WITH A CELL-BINDING MOLECULE WITH BRANCHED LINKERS
CY1122452T1 (en) OLIGOSACCHARITES CONTAINING AN AMINO ACID GROUP AND THEIR CONJUGATIONS
NZ754810A (en) Pyrrolobenzodiazepine-antibody conjugates
CY1112278T1 (en) Cytotoxic agents containing new tomomycin derivatives and their therapeutic use
AR089506A1 (en) A SPECIFIC GLP-2 CONJUGATE OF THE SITE USING AN IMMUNOGLOBULIN FRAGMENT
MX2024000877A (en) Cleavable polymer drug conjugates.
UA111341C2 (en) Conjugates of amatoxin with improved linkers
PE20170917A1 (en) ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES
BRPI0814252B8 (en) stable aqueous pharmaceutical composition comprising natalizumab, unit dose, and pre-filled syringe
MA40030A (en) Peptide-drug conjugates
MX2024003025A (en) Anti-her3 antibody drug conjugate, composition thereof, and use thereof.
CO2024005877A2 (en) Conjugates comprising phosphorus (v) and a drug molecular moiety
CL2022003411A1 (en) Bispecific antibody-drug conjugates targeting egfr and muc1 and their uses
ZA202101990B (en) Sulfomaleimide-based linkers and corresponding conjugates
MX2022008437A (en) Site specific antibody-drug conjugates with peptide-containing linkers.
MX2024015179A (en) Antibody drug conjugates
CR20250275A (en) NOVEL LINKING DEVICES FOR THE SUSTAINED DELIVERY OF THERAPEUTICS
CY1113275T1 (en) COGNITIVE PRODUCTS FOR MESHOTHERAPY TREATMENT
CO2024003299A2 (en) Anti-cd37 antibody-drug conjugate
CO2025014873A2 (en) Methods and compositions for targeted delivery using polymersomes
MX2022004341A (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy.
EA202092369A1 (en) PHOSPHOLIPID-FLAVAGLIN CONJUGATES AND METHODS FOR THEIR APPLICATION FOR TARGETED CANCER THERAPY